好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Ongoing Trial of Transcranial Magnetic Stimulation (TMS) for Chronic OroFacial Pain (COFP)
Pain
P1 - Poster Session 1 (8:00 AM-9:00 AM)
12-010

This double-blinded, randomized trial hypothesizes that 5 TMS treatments will provide a decrease in reported pain of COFP patients when compared to those who receive either an equivalent amount of sham or no stimulation while awaiting neurosurgical intervention.

Patients with COFP experience paroxysmal pain that significantly limits their quality of life. If the pain is not well controlled by medication, microvascular decompression, percutaneous procedures or stereotactic radiosurgery are typical lines of treatment (Brisman, 2013; Maarbjerg et al., 2017; Yu et al., 2019). However, there is routinely wait time for these elective procedures, during which pain remains uncontrolled. Although several studies indicate the safety and efficacy of TMS in the COFP population (Herrero Babiloni et al., 2018), none have proposed a practical application of this transient intervention for a chronic pain problem. The current trial is designed to further investigate the analgesic effect of TMS on COFP patients awaiting definitive neurosurgical intervention.

51 COFP patients presenting to the Carilion Clinic for neurosurgical intervention are randomized to one of three trial arms: standard care, 5 sessions of sham TMS, or 5 sessions of therapeutic TMS. Stimulation targets the M1 hand for a train of 100 20-Hz pulses once per minute for 10 consecutive minutes. Sham stimulation requires setting the TMS coil to non-stimulatory mode while transcutaneous electrical nerve stimulation (TENS) electrodes on the scalp mimic the sensation of stimulation. Patients and administrators are blinded to the sham versus stimulation group. Participant responses to the McGill Short Form Pain Questionnaire are recorded and compared before and after stimulation and surgery, across the three groups.

Pending.
Because there are currently no similarly powered, sham-controlled trials of TMS in this population, this trial will add robust data to the literature. Furthermore, this design proposes TMS as an interim, pre-surgical treatment for uncontrolled COFP.
Authors/Disclosures
Mallory E. Blackwood, MD (UCLA)
PRESENTER
Ms. Blackwood has nothing to disclose.
Mark Witcher (VaTech/Carilion Division of Neurosurgery) No disclosure on file